New injection shows promise for weight loss in early trial

NCT ID NCT06532578

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new drug called CPX101 in 240 overweight or obese adults without diabetes. Participants received different doses of CPX101 or a placebo by injection for 24 weeks. The goal was to see if the drug helps with weight loss and to check its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CPX101 (a biologic drug given by injection)

What this could lead to

If it works, this could lead to a new treatment option for weight loss in people who are overweight or obese.

What could go wrong

This is an early Phase 2 trial with only 240 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful weight loss compared to placebo.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Paratus Clinical Research

    Chatswood, New South Wales, Australia